Plus Therapeutics, Inc.
PSTV
$0.26
-$0.01-2.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.19% | -4.05% | 8.68% | -36.85% | 7.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.19% | -4.05% | 8.68% | -36.85% | 7.54% |
| Cost of Revenue | 34.54% | -14.77% | -55.07% | -36.45% | -21.76% |
| Gross Profit | -103.36% | 25.89% | 109.64% | 35.82% | 47.74% |
| SG&A Expenses | 33.33% | 43.64% | -23.65% | 28.29% | 31.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.83% | 11.87% | -41.16% | -7.66% | 2.73% |
| Operating Income | -47.23% | -17.98% | 58.40% | -7.18% | -1.09% |
| Income Before Tax | -46.37% | -53.90% | 275.20% | -433.61% | -2.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.37% | -53.90% | 275.20% | -433.61% | -2.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.37% | -53.90% | 275.20% | -433.61% | -2.44% |
| EBIT | -47.23% | -17.98% | 58.40% | -7.18% | -1.09% |
| EBITDA | -57.57% | -22.36% | 58.58% | -7.82% | 4.18% |
| EPS Basic | 91.64% | 88.74% | 105.44% | -3,811.41% | 41.40% |
| Normalized Basic EPS | 91.65% | 88.76% | 123.52% | -4,964.06% | 41.39% |
| EPS Diluted | 91.54% | 88.86% | 99.09% | -3,811.41% | 41.40% |
| Normalized Diluted EPS | 91.65% | 88.76% | 109.01% | -4,964.06% | 41.39% |
| Average Basic Shares Outstanding | 1,650.66% | 1,267.51% | 644.35% | -89.46% | 74.81% |
| Average Diluted Shares Outstanding | 1,650.66% | 1,267.51% | 1,846.91% | -89.46% | 74.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |